ASP:CA:TSX-Acerus Pharmaceuticals Corporation (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 0.06

Change

0.00 (0.00)%

Market Cap

CAD 0.08B

Volume

0.05M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

N/A

CAD13.36B N/A 17.61
WEED:CA Canopy Growth Corporation

N/A

CAD13.29B N/A N/A
APHA:CA Aphria Inc

N/A

CAD5.54B 57.08 598.01
CRON:CA Cronos Group Inc

N/A

CAD3.76B 46.76 N/A
ACB:CA Aurora Cannabis Inc

N/A

CAD1.95B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.94B -99,999.99 N/A
HEXO:CA HEXO Corp

N/A

CAD0.84B N/A N/A
CWEB:CA Charlotte's Web Holdings, Inc

N/A

CAD0.71B 120.37 N/A
GUD:CA Knight Therapeutics Inc

N/A

CAD0.68B 16.49 4.83
HLS:CA HLS Therapeutics Inc

N/A

CAD0.60B N/A 30.75

ETFs Containing ASP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.50% 59% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.50% 59% F 90% A-
Trailing 12 Months  
Capital Gain -9.85% 31% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.85% 31% F 4% F
Trailing 5 Years  
Capital Gain -62.88% 30% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.88% 30% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 1.60% 62% D- 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.60% 62% D- 34% F
Risk Return Profile  
Volatility (Standard Deviation) 79.71% 31% F 8% F
Risk Adjusted Return 2.00% 54% F 25% F
Market Capitalization 0.08B 27% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.00 64% D 84% B
Price/Book Ratio 21.38 10% F 4% F
Price / Cash Flow Ratio -3.82 33% F 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -231.82% 3% F 1% F
Return on Assets -88.23% 3% F 1% F
Debt to Equity Ratio 208.23% 24% F 10% F
Technical Ratios  
Short Ratio 0.45 83% B 65% D
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 81% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector